Fierce

Fierce Healthcare names Sesame a 2023 "Fierce 15" Company

Retrieved on: 
Tuesday, January 17, 2023
Insurance, Face, Health, Mental health, HDHP, Virtual reality, Fierce, Patient, Creativity, Dermatology, Health insurance, Sesame

NEW YORK, Jan. 17, 2023 /PRNewswire/ -- Sesame , the company building a radically new healthcare system for uninsured Americans and those with high-deductible plans, today announced that it has been named by Fierce Healthcare as one of the most promising healthcare companies in the industry for 2023, designating it as one of its annual Fierce 15 .

Key Points: 
  • NEW YORK, Jan. 17, 2023 /PRNewswire/ -- Sesame , the company building a radically new healthcare system for uninsured Americans and those with high-deductible plans, today announced that it has been named by Fierce Healthcare as one of the most promising healthcare companies in the industry for 2023, designating it as one of its annual Fierce 15 .
  • Sesame has been named one of the most promising healthcare companies in the industry for 2023 by Fierce Healthcare.
  • This is Fierce Healthcare's fifth annual Fierce 15 selection and represents many corners of the industry from virtual mental health to healthcare staffing and virtual reality.
  • An internationally-recognized daily report reaching a network of over 160,000 healthcare industry professionals, Fierce Healthcare provides subscribers with an authoritative analysis of the day's top stories.

CENTOGENE Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare Meeting and Fierce JPM Week in San Francisco

Retrieved on: 
Wednesday, December 28, 2022
U.S. Summit Company, Precision medicine, Drug discovery, Neurodegeneration, Fierce, Pharmaceutical industry

and ROSTOCK, Germany and BERLIN, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that its management team, including Chief Executive Officer Kim Stratton, will be attending the 41st Annual J.P. Morgan Healthcare Meeting, on January 9-12, 2023, in San Francisco, U.S.

Key Points: 
  • and ROSTOCK, Germany and BERLIN, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that its management team, including Chief Executive Officer Kim Stratton, will be attending the 41st Annual J.P. Morgan Healthcare Meeting, on January 9-12, 2023, in San Francisco, U.S.
  • The Company will also be attending the Fierce JPM Week.
  • CENTOGENE will meet with potential partners and investors to discuss the Company’s strategic developments aimed at providing data-driven, life changing answers to accelerate and de-risk drug discovery & development for the commercialization of precision medicine.
  • Please see additional details below:

Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

Retrieved on: 
Wednesday, December 21, 2022
Registration, Evaluation, Authorisation and Restriction of Chemicals, Sumathi Best Television Current Reporting Award, Webcast, Commercial, The Scientist (magazine), Health, Research, LLP, G&A, Acceleration, Marketing, Risk, R&D, CELL, Cell, Cell biology, Communication, Proteome, Multimedia, Sale, Organization, Intellectual property, Conference, Failure, Prospectus, JOINT, Customer base, HIV disease progression rates, Workflow, Oil, Security (finance), Management, Retail, Fine chemical, Video game console, Bank, Pharmaceutical industry, Fierce, Isoplexis, Shareholder

EMERYVILLE, Calif. and BRANFORD, Conn., Dec. 21, 2022 /PRNewswire/ -- Berkeley Lights (Nasdaq: BLI), a life sciences tools company, and IsoPlexis (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire IsoPlexis in an all-stock transaction valued at $57.8 million.

Key Points: 
  • The combined company, which will be named PhenomeX (Nasdaq: CELL), will be a premier functional cell biology company that provides live cell biology research tools which deliver deep insights into cellular function and new perspectives on phenomes.
  • As the combination of Berkeley Lights and IsoPlexis, PhenomeX's mission is to empower researchers to leverage the full potential of functional cell biology and shape the next wave of scientific revolution.
  • The combined company will unite complementary portfolios that will extend its leadership through the functional cell biology continuum with highly differentiated technology.
  • In connection with the proposed transaction between Berkeley Lights and IsoPlexis, Berkeley Lights and IsoPlexis intend to file relevant materials with the SEC, including a Berkeley Lights registration statement on Form S‑4 that will include a joint proxy statement of Berkeley Lights and IsoPlexis that also constitutes a prospectus of Berkeley Lights.

Lyndra Therapeutics’ LYNX™ Drug Delivery Platform Wins 2022 Fierce Life Sciences Innovation Award for Drug Delivery Technology

Retrieved on: 
Tuesday, November 15, 2022
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, SVP, Fierce, Fast Track, FDA, Malaria, GMP, Chicago Innovation Awards, Opioid use disorder, AbbVie, Engineering, Therapy, Thought disorder, Gilead Sciences, Pivotal, CNS, Research, Ivermectin, Face, NIH, Bill, Central nervous system, Public health, Schizophrenia, Buprenorphine, Patient, Pharmaceutical industry, Fine chemical

Lyndra Therapeutics today announced that its LYNX drug delivery platform was named the winner of the Fierce Life Sciences Innovation Awards 2022 award in the Drug Delivery Technology category.

Key Points: 
  • Lyndra Therapeutics today announced that its LYNX drug delivery platform was named the winner of the Fierce Life Sciences Innovation Awards 2022 award in the Drug Delivery Technology category.
  • It is an honor to have the platform selected by the Fierce award judges in such a competitive category.
  • The Fierce Life Sciences Innovation Awards, produced by Fierce Biotech and Fierce Pharma, showcase outstanding innovations that are transforming the life sciences industry.
  • The LYNX drug delivery platform harnesses more than 50 patented innovations in design, engineering and materials science to achieve dramatically reduced dosing frequency.

Wildflower Health Receives Prestigious Industry Award During HLTH 2022 for Excellence in Women's Health, Population Health Management, Patient Engagement

Retrieved on: 
Tuesday, November 15, 2022
Wildflower Film Awards, SAN, Kind + Jugend Innovation Award, Wildflower, Health, Technology, Face, SVP, Woman, Software, Industry, Fierce, Population health, Patient, CEO, Solution, Medicine

SAN FRANCISCO, Nov. 15, 2022 /PRNewswire-PRWeb/ -- Wildflower Health received a prestigious industry award during HLTH 2022 for its groundbreaking work in women's health and value-based maternity care. The Fierce Innovation Awards chose Wildflower as a category winner for the company's transformative value-based maternity care bundle.

Key Points: 
  • SAN FRANCISCO, Nov. 15, 2022 /PRNewswire-PRWeb/ -- Wildflower Health received a prestigious industry award during HLTH 2022 for its groundbreaking work in women's health and value-based maternity care.
  • The Fierce Innovation Awards chose Wildflower as a category winner for the company's transformative value-based maternity care bundle.
  • The solution helps patients actively participate in their health while equipping and empowering providers to deliver care the way they want.
  • Based on the strength of this bundle solution, the Fierce Innovation Awards: Healthcare Edition named Wildflower the winner of its Population Health Management/Patient Engagement category, which evaluated solutions for transparency, care management, patient education and social engagement.

IsoPlexis Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 10, 2022
Operating cost, Proteome, GLOBE, Private Securities Litigation Reform Act, Forward-looking statement, Health, Isoplexis, Director, U.S. Securities and Exchange Commission, Luminex Corporation, Nasdaq, Technology, Board, Proteomics, CodePlex, SEC, HIV disease progression rates, Board of directors, Nahum, Publication, Cell, The Scientist (magazine), Growth, CEO, Security (finance), Industry, Regulation, COVID-19, Renewable energy, Video game, Pharmaceutical industry, Risk management, Fierce

BRANFORD, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported financial results for the quarter ended September 30, 2022.

Key Points: 
  • BRANFORD, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported financial results for the quarter ended September 30, 2022.
  • Gross margin was 50% for the third quarter of 2022, as compared to 47% for the corresponding prior year period.
  • Total operating expenses were $19.2 million for the third quarter of 2022, representing a 12% reduction from the third quarter of 2021 and a 27% reduction from the second quarter of 2022.
  • IsoPlexis will host a conference call to discuss the third quarter 2022 financial results before market open on Thursday, November 10, 2022 at 5:30 am Pacific Time / 8:30 am Eastern Time.

IsoPlexis to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Proteome, Health, Isoplexis, Fireside chats, Nasdaq, HIV disease progression rates, Digital health, Evercore, Cell, Conference, The Scientist (magazine), Diagnosis, Pharmaceutical industry, Fierce

BRANFORD, Conn., Nov. 09, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will be participating in the following investor conferences.

Key Points: 
  • BRANFORD, Conn., Nov. 09, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will be participating in the following investor conferences.
  • IsoPlexis is empowering labs to leverage the cells and proteome changing the course of human health.
  • IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others.
  • The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies by revenue and 78% of leading U.S. comprehensive cancer centers.

Sagimet Biosciences Announces Appointment of David Happel to Chief Executive Officer; Dr. George Kemble to Transition to Executive Chairman Role

Retrieved on: 
Monday, October 24, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Therapy, Indiana State University, Organic acid, Patient, Horizon Therapeutics, MBA, List of life sciences, Fatty liver disease, Multimedia, Westlake Village, California, Inflammation, NASH, Fierce, MD, Doctor of Philosophy, Negotiation, Industry, CEO, BA, Autism, Chemistry, Interim, Fibrosis, Glioblastoma, Acne, FDA, FASN, Cancer, Pharmaceutical industry, Chiron, Indiana University

Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, announced today that it has appointed David Happel as chief executive officer, replacing George Kemble, PhD, who will transition to become executive chairman of the board.

Key Points: 
  • Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, announced today that it has appointed David Happel as chief executive officer, replacing George Kemble, PhD, who will transition to become executive chairman of the board.
  • View the full release here: https://www.businesswire.com/news/home/20221024005305/en/
    David Happel, chief executive officer of Sagimet Biosciences (Photo: Business Wire)
    We are pleased to welcome Dave as our new chief executive officer.
  • As Sagimet anticipates moving forward to late-stage clinical trials with our lead program, denifanstat, Daves experience will be instrumental to the companys growth.
  • We are fortunate to benefit from Georges continued contributions and expertise in his new role as executive chairman of the board.

IsoPlexis to Report Third Quarter 2022 Financial Results on November 10, 2022

Retrieved on: 
Wednesday, October 19, 2022
The Scientist (magazine), GLOBE, Proteome, Health, Webcast, HIV disease progression rates, Cell, Isoplexis, Nasdaq, Pharmaceutical industry, Fierce

BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will report financial results for the third quarter 2022 before market open on Thursday, November 10, 2022.

Key Points: 
  • BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will report financial results for the third quarter 2022 before market open on Thursday, November 10, 2022.
  • Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.
  • IsoPlexis is empowering labs to leverage the cells and proteome changing the course of human health.
  • IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others.

Fierce Whiskers Launches World's First Carbon-Negative Bourbon

Retrieved on: 
Friday, September 23, 2022
Carbon, Glass, Madison Brass Works, Organization, Grain, Barrel, Certification, Silent Scope 3, Carbon footprint, Map, 5, Water, Oil, Renewable energy, Fierce

AUSTIN, Texas, Sept. 23, 2022 /PRNewswire-PRWeb/ -- CarbonBetter, a minority-owned sustainability strategy and energy logistics firm, today announced the certification of the world's first carbon-negative bourbon distilled by Fierce Whiskers Distillery in Austin, Texas. Five O'Clock Shadow, a single-barrel bourbon release dropping exclusively at the company's first-anniversary event on September 24, 2022, also represents the first bourbon release for this grain-to-grass distillery.

Key Points: 
  • CarbonBetter today announced the certification of the world's first carbon-negative bourbon distilled by Fierce Whiskers Distillery in Austin, Texas.
  • AUSTIN, Texas, Sept. 23, 2022 /PRNewswire-PRWeb/ -- CarbonBetter , a minority-owned sustainability strategy and energy logistics firm, today announced the certification of the world's first carbon-negative bourbon distilled by Fierce Whiskers Distillery in Austin, Texas.
  • "At Fierce Whiskers, we are singularly focused on making the best possible whiskey in Austin, Texas.
  • The work to measure, reduce, and report on Fierce Whiskers' impacts set the stage to release a carbon-negative bourbon by leveraging carbon intensity calculations.